Deena Kuruvilla, AHS 2021: Results from the Phase 3 e-TNS trial for the Acute treatment of Migraine (TEAM)
touchNEUROLOGY had the pleasure to meet with Deena Kuruvilla (Westport Headache Institute, Westport, CT, USA) to discuss the phase 3 TEAM results investigating the Cefaly device as a non-pharmacological option for the prevention and acute treatment of migraine.
The abstract ‘A Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM)’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- What were the aims, methodology and inclusion criteria of the study you are presenting at AHS? (0:20)
- How well were the study endpoints met? (1:28)
- What unanswered questions remain regarding the Cefaly device and what future studies are planned? (2:45)
- What are your take home messages? (3:50)
Disclosures: Deena Kuruvilla is a medical advisor for Cefaly.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS 2021 (Virtual).
Share this Video
Related Videos In Headache Disorders
Stewart Tepper, AAN 2023: Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) summarizes the pivotal results of the PROGRESS phase 3 trial, evaluating the efficacy, safety, and tolerability of atogepant for preventive treatment of chronic migraine (CM). This study has very important clinical indications for the use of G pants in prevention of migraine. Atogepant […]
Atogepant for preventive treatment of chronic migraine, PROGRESS phase 3 trial: Richard Lipton, AAN 2023
Atogepant represents a relatively new class of medications called CGRP receptor antagonists, which have shown efficacy in preventing migraines. The PROGRESS phase 3 clinical trial assessed the efficacy of atogepant, an important new oral treatment option for the 8% of people with migraine who live with chronic migraine. Prof. Richard Lipton (Albert Einstein College of Medicine, […]
Stewart Tepper, AAN 2023: Results from the PRODROME trial of ubrogepant for the acute treatment of migraine
Prof Stewart Tepper (Geisal School of Medicine – Dartmouth, Hanover, NH, USA) shares one the most exciting presentations from the 75th AAN Annual Meeting, 2023. The results of the PRODROME study represent a paradigm shift in headache management and the data are a very exciting advance for headache and migraine specialists. Ubrogepant for the Acute Treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!